**BETA FINCH PODCAST SCRIPT**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into Philip Morris International's Q4 2025 earnings call. Now before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex! And what a call this was from Philip Morris. They absolutely crushed it in 2025, delivering what CEO Jacek Olczak called "another outstanding year." We're talking about their fifth consecutive year of positive volumes, driven primarily by their smoke-free products business.

**ALEX**: Right, and the numbers really tell the story here. Philip Morris hit over $40 billion in total net revenues for 2025, with smoke-free products now representing 41.5% of that - nearly $17 billion! That's a massive shift from where they were just a few years ago.

**JORDAN**: The growth trajectory is impressive. Smoke-free product volumes grew 12.8%, with IQOS leading the charge at 11% growth. But here's what caught my attention - their ZYN nicotine pouches in the US grew shipments by 37%, despite supply constraints. That's reaching 11.9 billion pouches, making up about 7% of their total smoke-free volume.

**ALEX**: And let's talk profitability because that's where this story gets really interesting. Their smoke-free gross margin hit 69.5%, which is now four percentage points higher than their combustible business. CFO Emmanuel Babeau made it clear that this improving profitability mix is a key driver of their overall margin expansion.

**JORDAN**: Speaking of margins, they delivered 140 basis points of organic margin expansion to reach 40.4% adjusted operating margin. That's while they're still investing heavily in marketing and brand building for their smoke-free portfolio. It shows real operating leverage in the business model.

**ALEX**: Now, the guidance for 2026 is where things get particularly interesting. They're forecasting organic net revenue growth of 5-7%, which might seem modest compared to recent years, but there are some specific headwinds they're navigating.

**JORDAN**: Exactly. The big story is Japan, where they're facing significant excise tax increases on heated tobacco products - we're talking 50-100 yen per pack, which could be 10-20% of current retail prices. This creates an asymmetry where heated tobacco gets hit first, before cigarettes face similar increases in 2027.

**ALEX**: And in the US, there's the ZYN inventory normalization. They estimate there are about 25 million cans of surplus inventory in the downstream supply chain that needs to work through, likely in Q1. But the underlying demand story remains strong - ZYN maintained about 61.5% volume share in the US nicotine pouch category.

**JORDAN**: What I found fascinating in the Q&A was the discussion around ZYN Ultra, their higher-strength nicotine pouch that's pending FDA approval. Olczak was pretty direct - they have readiness to launch "essentially as we speak," and they're expecting some movement this summer, though he admitted he doesn't have a great track record forecasting the FDA!

**ALEX**: [Laughs] At least he's honest about that! But you can tell they're frustrated with the regulatory environment. When asked about New York's proposed excise tax on nicotine pouches, Olczak called it "counterproductive to the health benefits" and "the wrong idea."

**JORDAN**: The international expansion story is really compelling too. They're now in 106 markets with smoke-free products, and some of these new launches are showing impressive traction. Taiwan caught my eye - they hit 4% market share in just a few weeks after launch. That's remarkable penetration for a new market entry.

**ALEX**: And they're not just focused on IQOS any

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into Procter & Gamble's Q2 2026 earnings call. Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And what a quarter to unpack! P&G just reported what management called their "softest quarter of the fiscal year," but there's actually a lot more optimism here than that headline might suggest.

**ALEX**: Absolutely. Let's start with the numbers, Jordan. Organic sales were flat year-over-year, which sounds underwhelming until you understand the context. They had some major base period disruptions - remember those port strikes and hurricanes last October that caused all that inventory loading?

**JORDAN**: Right, and CFO Andre Schulten was very clear about this. The biggest impacts hit baby care, feminine care, and family care - all concentrated in the U.S. market. But here's the interesting part: the rest of P&G's business outside the U.S. actually grew nearly 3%. That's a pretty solid foundation.

**ALEX**: That's a great point. When you look at the regional breakdown, you see some real bright spots. Latin America grew 8%, Greater China was up 3% - which is impressive given the challenging consumer environment there. Europe's enterprise markets grew 6%. It really was a U.S.-centric slowdown.

**JORDAN**: And speaking of China, I loved CEO Shailesh Jejurikar's example about their Pampers Prestige innovation. They tapped into this deep cultural insight about Chinese parents wanting the best for their babies, and literally incorporated silk - this symbol of luxury for over 2,000 years - into their diapers. It's driving double-digit growth and they've gained nearly three points of market share.

**ALEX**: That's exactly the kind of consumer-centric innovation P&G is doubling down on. Jejurikar talked extensively about what he called "the next important phase of constructive disruption." They're not just tweaking around the edges - they're fundamentally reimagining how a CPG company operates in today's fragmented media landscape.

**JORDAN**: The technology transformation really stood out to me. They've built this massive data lake with petabytes of consumer information, AI-powered tools for product development, and supply chain systems that can react autonomously to demand signals. But Jejurikar was realistic about the timeline - he said it'll take 12 to 18 months to get this "future evenly distributed" across the company.

**ALEX**: Let's talk margins for a second. Core EPS came in at $1.88, flat with last year. But they delivered 270 basis points of productivity improvements, which they reinvested back into innovation and marketing. That's classic P&G - they're not letting a tough quarter derail their long-term investment strategy.

**JORDAN**: And they're maintaining all their full-year guidance, which shows real confidence. Organic sales growth of flat to plus 4%, core EPS growth of flat to plus 4%. They're basically saying "trust us, the back half is going to be much stronger."

**ALEX**: The Q&A session revealed some interesting dynamics too. When analysts pressed about U.S. market share losses, Schulten was pretty direct - they have work to do to recover share, but they're already seeing progress in categories like family care and laundry where they've made those innovation interventions.

**JORDAN**: I thought the discussion about e-commerce was fascinating. One analyst pointed out that Amazon is driving 60-80% of growth in P&G's categories. Jejurikar's response was telling - they're being very deliberate about winning in fast-growing channels, and in some markets like India, their e-commerce share

This episode includes AI-generated content.

**Beta Finch Podcast Script: Altria (MO) Q4 2025 Earnings**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined by my co-host Jordan. Today we're diving into tobacco giant Altria's fourth quarter 2025 results. Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Thanks Alex. And wow, what a quarter for Altria. The company delivered some solid financials but also took a massive $1.3 billion impairment charge on their e-vapor business. That's not exactly chump change.

ALEX: Absolutely not. Let's start with the big picture numbers. Altria grew adjusted earnings per share by 4.4% for the full year and returned a whopping $8 billion to shareholders through dividends and share buybacks. That's serious cash returning to investors.

JORDAN: Right, and they're guiding for 2026 EPS between $5.56 and $5.72, which represents 2.5% to 5.5% growth. But here's the interesting part - CEO Billy Gifford said that growth will be "weighted to the second half of the year." That suggests a slower start to 2026.

ALEX: That timing issue ties into one of their big strategic moves. Altria is investing heavily in what they call "import-export capabilities" - basically a duty drawback program where they can manufacture cigarettes for international markets and then reimport them to get tax benefits. It's a complex play, but CFO Sal Mancuso said it has a payback period of less than a year.

JORDAN: That's actually pretty clever from a financial engineering standpoint. But let's talk about the elephant in the room - that $1.3 billion e-vapor impairment. They acquired NJOY to get into the vaping space, but the market is absolutely dominated by illegal flavored disposables from China.

ALEX: Exactly. Gifford said illegal products represent about 70% of the e-vapor category. Think about that - seven out of ten vaping products sold in the US are essentially operating outside FDA regulations. That makes it nearly impossible for legitimate companies like Altria to compete profitably.

JORDAN: But there might be a silver lining here. The company is seeing early signs that federal enforcement is starting to bite. Disposable e-vapor volume growth slowed from over 50% in 2024 to about 30% in 2025. Plus, Congress allocated at least $200 million in tobacco user fees specifically for enforcement activities.

ALEX: That enforcement angle is crucial for understanding Altria's strategy. They're basically saying "we'll wait on the sidelines until the government cleans up the illegal competition." Meanwhile, they're focusing on their nicotine pouch business, which is actually performing pretty well.

JORDAN: Speaking of nicotine pouches, their ON! brand is interesting. They got FDA authorization for ON! PLUS in December - that's their premium product with what they call "innovative pouch material and smooth flavor." They're positioning it as a premium option that can command higher prices than their classic ON! pouches.

ALEX: The numbers back that up. Helix, which makes the ON! products, shipped over 177 million cans for the full year, up about 11%. And while competitors were cutting prices - down 12% year-over-year according to Altria - they actually raised ON! prices by 3%.

JORDAN: But let's be real about the core business. Cigarette volumes declined 10% for the full year. That's a serious headwind. Even more concerning, Marlboro's retail share dropped below 40% for the first time ever.

ALEX: That Marlboro number caught my attention too. But Gifford pushed back on concerns during the Q&A, saying they're focused on "maximizing profitability over the long term" rather than chasing market share. They're also aggressively promoting their Basic discount brand in about 30,000 stores t

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn quarterly calls into coffee-shop conversations. I'm Alex, and I'm here with my co-host Jordan to break down 3M's Q4 2025 earnings call that just wrapped up. Jordan, this was one of those calls where the CEO really wanted to drive home that the turnaround is working.

**JORDAN:** Absolutely, Alex. And before we dive in, let me quickly mention - this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX:** Thanks for that reminder. Now, let's get into the numbers because 3M delivered some solid results here. Organic growth of 2.2% in Q4, operating margin of 21.1%, and earnings per share came in at $1.83. But the real story is the full-year performance - they grew organic sales 2.1% for the year, which is a nice acceleration from that 1.2% they posted in 2024.

**JORDAN:** What really caught my attention was the margin expansion story. They delivered 23.4% adjusted operating margin for the full year - that's up 200 basis points year-over-year and at the high end of their guidance. CEO Bill Brown has been hammering this "commercial excellence" message for the past 21 months, and it seems like it's actually working.

**ALEX:** Yeah, and let's talk about innovation because this is where things get interesting. They launched 284 new products in 2025 - that's up 68% from the prior year. Brown was pretty excited about this, saying sales from products launched in the last five years were up 23% for the full year.

**JORDAN:** That's a key metric to watch, Alex. They call it their "new product vitality index" or NPVI, and it hit 13% - about two points above where they started the year. But here's what I found fascinating - Brown said about 80% of their R&D spending is now focused on what they call "priority verticals" - the higher-growth, higher-margin areas.

**ALEX:** Right, and speaking of those priority verticals, they represent about 60% of the business now. Brown hinted that there's going to be some portfolio reshuffling ahead. He mentioned about 10% of their business is in more commodity-like areas that they're probably going to think about exiting over time.

**JORDAN:** The operational metrics were impressive too. Their OTIF - that's on-time, in-full delivery - hit 90%, up 300 basis points from the prior year. Brown called it "the best we've achieved in decades" and they sustained that rate for seven months straight. That's the kind of operational excellence that actually moves the needle with customers.

**ALEX:** Now let's talk guidance because this is where it gets really interesting for investors. For 2026, they're calling for organic sales growth of approximately 3% - so accelerating from that 2.1% they just posted. They expect adjusted operating margin expansion of 70 to 80 basis points, and EPS of $8.50 to $8.70.

**JORDAN:** What I like about this guidance is the confidence in their "outgrowth" strategy. Brown said they expect the macro environment to be around 1.7% growth, but they're guiding to 3% organic growth. That delta - over $300 million - is what he calls outperforming the macro, and about half of that is coming from new product introductions.

**ALEX:** The Q&A had some interesting moments too. There were several questions about tariffs, which makes sense given the current political environment. Brown said they're already dealing with about $140 million in gross tariff impact, and there could be additional headwinds if new Europe tariffs get implemented.

**JORDAN:** Yeah, Brown was pretty measured on that topic. He said if the proposed Europe tariffs play out as discussed - 10% initially, then up to 25% - it could be a $30 to $40 million impact in 2026. But he emphasized that's not in their gui

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

**[INTRO MUSIC]**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into McDonald's Q4 2025 results. Jordan, this was quite the quarter for the Golden Arches.

JORDAN: Absolutely, Alex! And before we dig in, I need to mention - this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Thanks for that reminder, Jordan. Now, let's talk numbers. McDonald's delivered some impressive results - system-wide sales hit nearly $140 billion, up 5.5% in constant currency for the full year. But what really caught my eye was that Q4 comp sales growth of 5.7% globally. That's pretty strong in what they're calling a "challenging industry backdrop."

JORDAN: Right, and breaking that down by segment - the U.S. was particularly strong at 6.8% comp growth, well above expectations. What's interesting is they had positive guest counts, which is always a key indicator of sustainable growth. CEO Chris Kempczinski mentioned they achieved their highest quarterly comparable guest count gap to competitors "in recent history."

ALEX: That's a fancy way of saying they're stealing customers from the competition! And speaking of the U.S., their value strategy seems to be working. They launched McValue early in the year, then relaunched Extra Value Meals in September. The results? They gained share with low-income consumers in December and saw meaningful improvement in value and affordability scores.

JORDAN: The marketing machine was firing on all cylinders too. The MONOPOLY promotion became one of their largest digital customer acquisition events ever - they now have 46 million 90-day active users in their U.S. loyalty app alone. But get this - the Grinch Meal campaign set new sales records, including the highest single sales day in McDonald's history!

ALEX: 50 million pairs of Grinch-themed socks sold globally! They literally became the largest seller of socks in the world for nearly a week. Only McDonald's could pull that off.

JORDAN: The international segments held up well too. International Operated Markets grew comp sales 5.2% - that's three consecutive quarters above 4% growth. The U.K., Germany, and Australia all delivered mid-to-high single-digit comp growth, with each market gaining market share.

ALEX: Now, let's talk about what's coming next because this is where it gets really interesting. They're accelerating restaurant openings - targeting 2,600 gross openings in 2026, up from 2,275 in 2025. That puts them on track for 50,000 restaurants by end of 2027.

JORDAN: The capital expenditure guidance reflects this growth - they're expecting $3.7 to $3.9 billion in CapEx for 2026, up from $3.4 billion in 2025. CFO Ian Borden was clear this increase was planned and keeps them on track with their December 2023 investor day targets.

ALEX: But here's what I found most intriguing - the menu innovation pipeline. New Chief Restaurant Experience Officer Jill McDonald outlined some ambitious plans. They're rolling out "Best Burger" to nearly all markets by end of 2026, and the Big Arch burger is gaining permanent spots on menus after successful pilots.

JORDAN: And beverages - this could be huge, Alex. They're targeting a $100 billion global beverage opportunity with new offerings under the McCafe brand. Energy drinks, indulgent iced coffees, fruity refreshers, crafted sodas. They even mentioned continuing their Red Bull collaboration. Their beverage test in 500+ U.S. restaurants exceeded expectations and drove incremental occasions across different dayparts.

ALEX: The chicken category focus is smart too - it's twice the size of beef and faster growing. They grew chicken category share across their top 10 markets in 2025 and are targeting at least 1 percen

This episode includes AI-generated content.

**Beta Finch - Episode 127: Coca-Cola Q4 2025**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the corporate speak to bring you what really matters. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Coca-Cola's Q4 2025 earnings call - and wow, what a historic moment this was.

**ALEX:** Absolutely. Before we jump in though, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** So Alex, let's start with the elephant in the room - this was CEO James Quincey's final earnings call after a decade at the helm.

**ALEX:** Right, and what a send-off! Quincey handed the reins to Henrique Braun, who's been with the company for over 30 years. But let's talk numbers first - Coca-Cola delivered on both their top and bottom line guidance for 2025, which is no small feat given the challenging macro environment.

**JORDAN:** The headline numbers are solid. They achieved 4% comparable earnings per share growth despite facing 5 points of currency headwinds and a 2-point increase in their tax rate. That's actually pretty impressive when you break it down.

**ALEX:** And they maintained their streak of gaining value share for 19 consecutive quarters. That's nearly five years of consistently winning market share, Jordan.

**JORDAN:** Let's dig into the Q4 specifics because there's an interesting story in the price-mix numbers. They reported only 1% price-mix growth, but CFO John Murphy clarified that underlying pricing was actually 4%, with a 3% negative mix impact from geography and timing issues.

**ALEX:** That's a perfect example of why Quincey urged analysts to take a "4-quarter view" rather than getting caught up in quarterly noise. When you smooth out the mix effects, you see consistent 5% revenue growth, which aligns with their long-term algorithm.

**JORDAN:** Speaking of long-term, let's talk about their 2026 guidance. They're projecting 4% to 5% organic revenue growth and 7% to 8% comparable EPS growth. But here's the kicker - they're expecting a more balanced mix between volume and pricing going forward.

**ALEX:** That's a key shift, Jordan. For the past few years, they've been heavily price-driven due to inflation. Now they're signaling a return to more balanced growth, which suggests they believe they can start winning back volume while maintaining pricing power.

**JORDAN:** But it's not all smooth sailing. They're facing some headwinds in key markets. Mexico is implementing an excise tax that will pressure volumes, China continues to see softer consumer spending, and India needs to rebuild momentum after a challenging 2025.

**ALEX:** New CEO Henrique Braun was pretty candid about this. He mentioned that their "all-weather strategy" helps them leverage strong markets to offset weaker ones. It's essentially a global portfolio approach - when one region struggles, others can pick up the slack.

**JORDAN:** Let's talk about innovation because Braun made some interesting comments here. He said their innovation "is not where it needs to be" and they need to get closer to consumers and improve speed to market.

**ALEX:** That was refreshingly honest. He talked about wanting to better anticipate the next growth opportunities in beverages and be more proactive rather than reactive. They announced two new billion-dollar brands - innocent and Santa Clara from Mexico - bringing their total to 32 billion-dollar brands.

**JORDAN:** The Mexico example is fascinating because Santa Clara started as a local value-added dairy brand and grew into a billion-dollar business. That's exactly the playbook Braun wants to replicate - start local, learn what works, then scale globally.

**ALEX:** Now let's talk about North America, which has been a real bright spo

This episode includes AI-generated content.

**Beta Finch Podcast Script: Johnson & Johnson Q4 2025**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and joining me as always is my co-host Jordan. Today we're dissecting Johnson & Johnson's Q4 2025 earnings call, and wow - what a way to cap off the year.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Thanks Alex, and yeah, JNJ really delivered here. They're calling 2025 a "catapult year" - and the numbers back that up. Let's start with the headline figures because they're impressive across the board.

ALEX: Absolutely. Fourth quarter operational sales growth came in at 7.1%, which is solid, but the full-year picture is even better. They hit $94.2 billion in total revenue for 2025 with 5.3% operational growth. But here's the kicker, Jordan - they're guiding for $100 billion at the midpoint for 2026. That's a massive psychological milestone for any healthcare company.

JORDAN: Right, and what's fascinating is how they're positioning this growth. CEO Joaquin Duato kept emphasizing their "28 billion-dollar products" - that's an incredible diversification of revenue streams. No other healthcare company has that kind of breadth. They're not relying on one or two blockbusters like some of their competitors.

ALEX: Let's break down the two main segments. On the Innovative Medicine side, they posted 5.3% operational growth for the year, crossing $60 billion in pharma sales for the first time. The star performer here continues to be DARZALEX in multiple myeloma - $14 billion in annual sales with 22% growth. That's just staggering for a drug of that size.

JORDAN: And they're not stopping there. The multiple myeloma franchise is becoming a juggernaut. They mentioned being the number one company in that space, with 80% of patients treated with at least one of their four medicines. Plus, CARVICTI, their CAR-T therapy, is showing strong momentum with over 10,000 patients treated across 14 markets.

ALEX: The immunology story is equally compelling. Tremfya hit $5 billion in sales and grew 65% in Q4 - that's not a typo, sixty-five percent! They're confident it'll exceed $10 billion in peak sales, especially as it continues taking share in inflammatory bowel disease where STELARA used to dominate.

JORDAN: Speaking of STELARA, that's the elephant in the room that's actually becoming less relevant. STELARA declined 48.6% due to biosimilar competition, but here's what's remarkable - JNJ grew double digits for the full year excluding STELARA. They've successfully navigated that cliff, which was a major investor concern.

ALEX: Now let's talk MedTech. 5.4% operational growth for the year with some really strong pockets. Cardiovascular was the standout with 15% operational growth, reaching $9 billion. The Abiomed and Shockwave acquisitions are clearly paying dividends here.

JORDAN: What caught my attention was their robotics ambition. They just submitted their Ottava robotic surgery system for FDA approval via a de novo pathway - meaning there's no predicate device to compare it against. That suggests they truly believe they have something differentiated in a space dominated by Intuitive Surgical.

ALEX: The guidance for 2026 is aggressive but achievable based on their pipeline momentum. 5.7% to 6.7% operational sales growth, with that $100 billion midpoint I mentioned. Adjusted EPS growth of 5.5% at the midpoint, which factors in about $500 million in medtech tariffs - significantly higher than 2025.

JORDAN: I want to highlight something CFO Joe Wolk said about margins. They're expecting at least 50 basis points of adjusted operating margin improvement despite those tariff headwinds and increased investment in

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into Colgate-Palmolive's Q4 2025 results. Now, before we get into the toothpaste and pet food numbers, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And speaking of brushing up on the details, Colgate just wrapped up what CEO Noel Wallace called a "stronger-than-expected Q4" despite some pretty challenging headwinds. The big story here isn't just the quarter though - it's their new 2030 strategy they're launching.

**ALEX**: Right, so let's start with the numbers. What stood out to you from the quarter?

**JORDAN**: Well, the momentum story is compelling. They saw sequential improvement in organic sales growth across most regions - hitting over 3% organic growth when you exclude their planned exit from private label business. That's a nice acceleration from Q3. And importantly, they delivered modest volume growth in Q4, which is no small feat in this environment.

**ALEX**: And the cash flow performance was pretty impressive too, right?

**JORDAN**: Absolutely stellar - record operating cash flow of $4.2 billion. That's giving them serious flexibility for reinvestment and potential acquisitions. Wallace kept emphasizing this "flexibility" theme throughout the call.

**ALEX**: Now, the guidance for 2026 was interesting - they gave a pretty wide range of 1% to 4% for organic sales growth. That's unusually broad for Colgate.

**JORDAN**: Yeah, and Wallace was refreshingly transparent about why. He basically said: if categories get worse, they'll be at the low end. If categories stay where they are, they'll be in the middle. If categories strengthen, they hope to hit the higher end. It's a simple framework, but it shows just how uncertain they feel about the consumer environment right now.

**ALEX**: Speaking of uncertainty, the U.S. market seems to be their biggest challenge. What's happening there?

**JORDAN**: It's pretty stark. Wallace mentioned that nine of their categories were down in volume in October, ten in November. The North American business is clearly struggling with what he called "consumer uncertainty." People are holding back on filling their pantries, buying more on promotion, and there's this general sluggishness in category growth.

**ALEX**: But there were some bright spots internationally, weren't there?

**JORDAN**: Definitely. Latin America had a really strong quarter - both Mexico and Brazil growing high single digits. And their emerging markets overall grew about 4.5% organically with good balance between price and volume. It's that classic story of developed markets struggling while emerging markets show more resilience.

**ALEX**: The Hill's pet food business also seemed to perform well despite a tough category backdrop.

**JORDAN**: Hill's was a standout - over 5% growth excluding private label, with positive volume growth. Their prescription diet business is really driving growth, and that higher-margin therapeutic segment is exactly where you want to see momentum. Wallace mentioned they're gaining share across all channels.

**ALEX**: Now, let's talk about this 2030 strategy they unveiled. It sounds like a pretty significant shift.

**JORDAN**: It's fascinating - they're basically reorganizing around what they call "omnichannel demand generation." Instead of having separate e-commerce and brick-and-mortar teams, they're creating one integrated commercial organization. Wallace said they've been sending leaders to China to learn from their team there, which has figured out how to excel in both traditional retail and online.

**ALEX**: And they're backing this up with their St

This episode includes AI-generated content.

**Beta Finch Podcast Script: Abbott Laboratories Q4 2025 Earnings**

---

**ALEX:** Welcome back to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and as always, I'm joined by my co-host Jordan. Today we're unpacking Abbott's fourth quarter 2025 results, and folks, there's quite a story here.

Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Now Jordan, Abbott just reported their Q4 numbers, and CEO Robert Ford had some interesting things to say about the year ahead. What caught your attention first?

**JORDAN:** Alex, the headline numbers tell a tale of two companies, honestly. On one hand, you've got Abbott delivering on their original double-digit EPS growth target with adjusted earnings per share hitting $1.50 – that's 12% growth year-over-year. But then there's this nutrition business headwind that's creating some near-term challenges.

**ALEX:** Right, and let's talk about that guidance because it's pretty telling. For 2026, Abbott is projecting organic sales growth of 6.5% to 7.5% – so 7% at the midpoint – and they're calling for 10% growth in adjusted EPS. That EPS growth is solid, but that revenue guidance seems a bit more cautious than what some were expecting.

**JORDAN:** Exactly, and Ford was pretty transparent about why. The nutrition business is essentially going through what he called a "transition back to a more sustainable volume-driven business." Here's what's fascinating – Abbott has been raising prices to offset post-pandemic commodity cost increases, but now those higher prices are actually suppressing demand as consumers become more price-sensitive.

**ALEX:** It's like a classic consumer goods dilemma, right? You raise prices to maintain margins, but eventually you price yourself out of volume growth. Ford mentioned they started implementing "price and promotion initiatives" in Q4 to try to reignite volume growth. How big of an impact is this having on the overall company?

**JORDAN:** Well, nutrition is a meaningful piece of Abbott's portfolio, but what I found encouraging is how Ford framed the rest of the business. He said a "significant majority of the company" is either maintaining high single-digit growth or actually accelerating. The medical devices segment, for example, grew 10.5% in the quarter.

**ALEX:** And that medical devices growth is really impressive when you dig into the details. Continuous glucose monitors grew 17% for the full year, exceeding $7.5 billion in sales. That's the third consecutive year their CGM business has grown by more than a billion dollars. Jordan, when an analyst asked about CGM growth expectations, Ford had a pretty confident response.

**JORDAN:** He did! Ford pushed back on the narrative that the CGM market is slowing down, saying "I don't consider growing a billion dollars every single year and doing it four years in a row to be slowing down." He sees continued penetration opportunities across all patient groups – intensive insulin users, basal insulin users, and non-insulin users. Plus, there's potential for expanded reimbursement coverage for non-insulin Type 2 diabetes patients.

**ALEX:** Speaking of new products, Abbott got FDA approval for their BOLT PFA catheter in December and CE Mark approval for their Tactiflex Duo ablation catheter. Ford seemed pretty excited about their electrophysiology portfolio positioning.

**JORDAN:** Absolutely. He made this great point about how three years ago, there were concerns that Abbott's EP franchise would struggle without PFA technology, but they've maintained double-digit growth even without those products. Now with Volt launching in the US and Tactiflex Duo internationally, Ford said "I do

This episode includes AI-generated content.